Literature DB >> 2507472

Disposition of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in mice.

S M el Dareer1, K F Tillery, J R Kalin, D L Hill.   

Abstract

Mice were dosed with [3H]2',3'-dideoxyadenosine ([3H]ddA) in three procedures: intravenously, intraperitoneally, and interperitoneally following a dose of 2'-deoxycoformycin (dCF). For mice dosed intravenously, the content of radioactivity in plasma and tissue samples were essentially constant after 30 min. Of the radioactivity in plasma and brain samples collected between 30 min and 24 hr, more than 94% was present as 3H2O, indicating that most of the tritium from [3H]ddA had exchanged with water. No intact ddA was detected, and the deamination product, 2',3'-dideoxyinosine (ddI), was present only transiently. In the urine, the major radioactive material was [3H]ddI. Also detected were 3H2O and small amounts of [3H]hypoxanthine and [3H]ddA. Following intraperitoneal doses to mice, levels of radioactivity in plasma, liver, and kidney increased to a maximum by 15-30 min after dosing but dropped to essentially constant levels thereafter, again indicating that the tritium had exchanged with water. At 5, 15, and 30 min after dosing, ddI was the major radioactive component in plasma. Only small amounts of ddA were present. When dCF was administered 24 hr prior to intraperitoneal [3H]ddA, levels of radioactivity in plasma, liver, and kidney reached a maximum of 30 to 60 min after dosing and decreased to essentially constant levels thereafter. The dCF transiently inhibited the deamination of ddA to ddI, since, in plasma, [3H]ddA was the main radioactive component at 5 and 15 min after dosing. Comparison of HPLC assays based on radioactivity detection and UV absorbance showed that they were equivalent for measuring ddA and ddI in samples derived from dosed mice.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2507472     DOI: 10.1007/bf00170850

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN: 0167-6997            Impact factor:   3.850


  7 in total

1.  Initial studies on the cellular pharmacology of 2',3'-dideoxyadenosine, an inhibitor of HTLV-III infectivity.

Authors:  D A Cooney; G Ahluwalia; H Mitsuya; A Fridland; M Johnson; Z Hao; M Dalal; J Balzarini; S Broder; D G Johns
Journal:  Biochem Pharmacol       Date:  1987-06-01       Impact factor: 5.858

2.  Human erythrocytic purine nucleoside phosphorylase: reaction with sugar-modified nucleoside substrates.

Authors:  J D Stoeckler; C Cambor; R E Parks
Journal:  Biochemistry       Date:  1980-01-08       Impact factor: 3.162

3.  Both 2',3'-dideoxythymidine and its 2',3'-unsaturated derivative (2',3'-dideoxythymidinene) are potent and selective inhibitors of human immunodeficiency virus replication in vitro.

Authors:  M Baba; R Pauwels; P Herdewijn; E De Clercq; J Desmyter; M Vandeputte
Journal:  Biochem Biophys Res Commun       Date:  1987-01-15       Impact factor: 3.575

4.  Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2',3'-dideoxynucleosides.

Authors:  H Mitsuya; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1986-03       Impact factor: 11.205

5.  Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.

Authors:  W Plunkett; S S Cohen
Journal:  Cancer Res       Date:  1975-06       Impact factor: 12.701

6.  Long-term inhibition of human T-lymphotropic virus type III/lymphadenopathy-associated virus (human immunodeficiency virus) DNA synthesis and RNA expression in T cells protected by 2',3'-dideoxynucleosides in vitro.

Authors:  H Mitsuya; R F Jarrett; M Matsukura; F Di Marzo Veronese; A L DeVico; M G Sarngadharan; D G Johns; M S Reitz; S Broder
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

7.  The anti-HTLV-III (anti-HIV) and cytotoxic activity of 2',3'-didehydro-2',3'-dideoxyribonucleosides: a comparison with their parental 2',3'-dideoxyribonucleosides.

Authors:  J Balzarini; G J Kang; M Dalal; P Herdewijn; E De Clercq; S Broder; D G Johns
Journal:  Mol Pharmacol       Date:  1987-07       Impact factor: 4.436

  7 in total
  3 in total

1.  Effects of 2',3'-dideoxyinosine on Toxoplasma gondii cysts in mice.

Authors:  M E Sarciron; P Lawton; C Saccharin; A F Petavy; F Peyron
Journal:  Antimicrob Agents Chemother       Date:  1997-07       Impact factor: 5.191

2.  Nonlinear disposition of intravenous 2',3'-dideoxyinosine in rats.

Authors:  M G Wientjes; E Mukherji; J L Au
Journal:  Pharm Res       Date:  1992-08       Impact factor: 4.200

3.  Disposition and metabolism in mice of the potential antitumor and anti-human immunodeficiency virus-1 agent, 2-chloro-2',3'-dideoxyadenosine.

Authors:  D E Chapman; G Powis
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.